| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | MITOTHERAPEUTIX, LLC | 400 FARMINGTON AVE | FARMINGTON | CT | 06032-1913 | CAPITOL | USA | R41AA030517 | Novel Treatment for Alcohol-associated Liver Disease | 000 | 1 | NIH | 11/1/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,282,898 ) |
| | 2023 | 2023 | MITOTHERAPEUTIX LLC | 400 FARMINGTON AVE | FARMINGTON | CT | 06032-1913 | CAPITOL | USA | R44DK129102 | A novel approach to treat non-alcoholic steatohepatitis (NASH) | 000 | 3 | NIH | 2/28/2023 | $1,008,980 |
| | 2023 | 2023 | MITOTHERAPEUTIX LLC | 400 FARMINGTON AVE | FARMINGTON | CT | 06032-1913 | CAPITOL | USA | R41AA030517 | Novel Treatment for Alcohol-associated Liver Disease | 000 | 1 | NIH | 3/15/2023 | $273,918 |
|
| Issue Date FY: 2022 ( Subtotal = $860,261 ) |
| | 2022 | 2022 | MITOTHERAPEUTIX LLC | 400 FARMINGTON AVE | FARMINGTON | CT | 06032-1913 | CAPITOL | USA | R44DK129102 | A novel approach to treat non-alcoholic steatohepatitis (NASH) | 001 | 2 | NIH | 5/28/2022 | $860,261 |
| | 2022 | 2021 | MITOTHERAPEUTIX LLC | 400 FARMINGTON AVE | FARMINGTON | CT | 06032-1913 | CAPITOL | USA | R44DK129102 | A novel approach to treat non-alcoholic steatohepatitis (NASH) | 000 | 1 | NIH | 10/15/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $253,050 ) |
| | 2021 | 2021 | MITOTHERAPEUTIX LLC | 400 FARMINGTON AVE | FARMINGTON | CT | 06032-1913 | CAPITOL | USA | R44DK129102 | A novel approach to treat non-alcoholic steatohepatitis (NASH) | 000 | 1 | NIH | 5/26/2021 | $253,050 |
| | 2021 | 2018 | MITOTHERAPEUTIX LLC | 400 FARMINGTON AVE | FARMINGTON | CT | 06032-1913 | CAPITOL | USA | R41DK117760 | A Novel Treatment for Acetominophen-Induced Liver Injury | 000 | 1 | NIH | 7/1/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2018 | MITOTHERAPEUTIX LLC | 400 FARMINGTON AVE | FARMINGTON | CT | 06032-1913 | CAPITOL | USA | R41DK117760 | A Novel Treatment for Acetominophen-Induced Liver Injury | 003 | 1 | NIH | 7/29/2020 | $0 |
| | 2020 | 2018 | MITOTHERAPEUTIX LLC | 400 FARMINGTON AVE | FARMINGTON | CT | 06032-1913 | CAPITOL | USA | R41DK117760 | A Novel Treatment for Acetominophen-Induced Liver Injury | 000 | 1 | NIH | 1/9/2020 | $0 |
| | 2020 | 2018 | MITOTHERAPEUTIX LLC | 400 FARMINGTON AVE | FARMINGTON | CT | 06032-1913 | CAPITOL | USA | R41DK117760 | A Novel Treatment for Acetominophen-Induced Liver Injury | 002 | 1 | NIH | 7/16/2020 | $0 |
| | 2020 | 2018 | MITOTHERAPEUTIX LLC | 400 FARMINGTON AVE | FARMINGTON | CT | 06032-1913 | CAPITOL | USA | R41DK117760 | A Novel Treatment for Acetominophen-Induced Liver Injury | 001 | 1 | NIH | 7/15/2020 | $0 |
| | 2020 | 2017 | MITOTHERAPEUTIX LLC | 400 FARMINGTON AVE | FARMINGTON | CT | 06032-1913 | CAPITOL | USA | R41DK112429 | A novel approach to treat non-alcoholic steatohepatitis (NASH) | 000 | 1 | NIH | 12/17/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $264,238 ) |
| | 2018 | 2018 | MITOTHERAPEUTIX LLC | 400 FARMINGTON AVE | FARMINGTON | CT | 06032-1913 | CAPITOL | USA | R41DK117760 | A Novel Treatment for Acetominophen-Induced Liver Injury | 000 | 1 | NIH | 6/19/2018 | $264,238 |
|
| Issue Date FY: 2017 ( Subtotal = $317,953 ) |
| | 2017 | 2017 | MITOTHERAPEUTIX LLC | 400 FARMINGTON AVE | FARMINGTON | CT | 06032-1913 | CAPITOL | USA | R41DK112429 | A novel approach to treat non-alcoholic steatohepatitis (NASH) | 000 | 1 | NIH | 6/30/2017 | $317,953 |
|
|
